Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.AbbVie has partnered with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a monoclonal antibody therapeutic for the prevention and treatment of Covid-19.
AbbVie and its collaborators will advance a fully human, neutralising antibody, 47D11, which acts on Covid-19 through the conserved domain of the SARS-CoV-2’s spike protein, discovered by HBM, UU and EMC.
As part of the alliance, AbbVie will work with HBM, UU and EMC through the preclinical activities and will make preparations for late-stage preclinical and clinical development.